Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

Impact of NFE2 mutations on AML transformation and overall survival in patients with myeloproliferative neoplasms

Blood (2021) 138 (21): 2142–2148.

https://doi.org/10.1182/blood.2020010402

Published: 2021

Includes: Supplemental data

Journal Articles

Chronic Exposure to Cytoreductive Treatment Shapes Clonal Evolution in Myeloproliferative Neoplasms

Lin-Pierre Zhao, Nabih Maslah, Rafael Daltro De Oliveira, Emmanuelle Verger, Juliette Soret-Dulphy, Clemence Marcault, Nathalie Parquet, Christine Dosquet, William Vainchenker, Emmanuel Raffoux, Stephane Giraudier, Jean-Jacques Kiladjian, Bruno Cassinat, Lina Benajiba, Marine Cazaux

Blood (2021) 138 (Supplement 1): 3620.

https://doi.org/10.1182/blood-2021-152622

Published: 2021

Journal Articles

Myeloproliferative Neoplasms (MPN) Clonal Evolution Landscape and Its Impact on Patients' Prognosis

Lin-Pierre Zhao, Marine Cazaux, Nabih Maslah, Rafael Daltro De Oliveira, Emmanuelle Verger, Juliette Soret-Dulphy, Clemence Marcault, Nathalie Parquet, Christine Dosquet, William Vainchenker, Emmanuel Raffoux, Stephane Giraudier, Jean-Jacques Kiladjian, Bruno Cassinat, Lina Benajiba

Blood (2021) 138 (Supplement 1): 317.

https://doi.org/10.1182/blood-2021-149473

Published: 2021

Journal Articles

NFE2 Mutations Impact AML Transformation and Overall Survival in Patients with Myeloproliferative Neoplasms (MPN)

Clemence Marcault, MD, Lin-Pierre Zhao, MD, Rafael Daltro De Oliveira, MD, Juliette Soret, MD, Nicolas Gauthier, MD, Emmanuelle Verger, PhD, Nabih Maslah, PharmD, Blandine Roux, MSc, Nathalie Parquet, MD, Christine Dosquet, MD, Delphine Rea, MDPhD, Jean-Marc Zini, William Vainchenker, Emmanuel Raffoux, MD, Stephane Giraudier, MD PhD, Bruno Cassinat, PharmD, PhD, Jean-Jacques Kiladjian, Lina Benajiba, MD PhD

Blood (2020) 136 (Supplement 1): 36.

https://doi.org/10.1182/blood-2020-136177

Published: 2020

Journal Articles

SF3B1 mutations in the Driver Clone Increase the Risk of Evolution to Myelofibrosis in Patients with Myeloproliferative Neoplasms (MPN)

Lin-Pierre Zhao, MD, Rafael Daltro De Oliveira, MD, Clemence Marcault, MD, Juliette Soret, MD, Nicolas Gauthier, MD, Emmanuelle Verger, PhD, Nabih Maslah, PharmD, Blandine Roux, MSc, Nathalie Parquet, MD, Christine Dosquet, MD, Delphine Rea, MDPhD, Jean-Marc Zini, MD, William Vainchenker, Emmanuel Raffoux, MD, Stephane Giraudier, MD PhD, Bruno Cassinat, PharmD, PhD, Jean-Jacques Kiladjian, MD PhD, Lina Benajiba, MD PhD

Blood (2020) 136 (Supplement 1): 1.

https://doi.org/10.1182/blood-2020-141296

Published: 2020

Journal Articles

Long Term Outcome of Patients with MPN-Associated Myelofibrosis Treated with Peg-Interferon-α2a, a French Intergroup of Myeloproliferative Neoplasms (FIM) Study

Blood (2017) 130 (Supplement 1): 323.

https://doi.org/10.1182/blood.V130.Suppl_1.323.323

Published: 2017

Journal Articles

Outcomes of Patients with Myeloproliferative Neoplasms (MPN) after Interferon-Alpha (IFN) Therapy Discontinuation

Juliette Soret, MD, Bruno Cassinat, PharmD, PhD, Sylvie Chevret, MD PhD, Christine Dosquet, MD PhD, Stephane Giraudier, MD PhD, Emmanuelle Verger, PhD, Nabih Maslah, PhD, Nathalie Parquet, MD, Christine Chomienne, MD PhD, Jean-Jacques Kiladjian, MD PhD

Blood (2016) 128 (22): 3106.

https://doi.org/10.1182/blood.V128.22.3106.3106

Published: 2016

Journal Articles

Autologous 111 Indium-Oxinate-Labelled Platelet Sequestration Study in Patients with Immune Thrombocytopenia Treated By Thrombopoietic Receptor-Agonists

Blood (2016) 128 (22): 2555.

https://doi.org/10.1182/blood.V128.22.2555.2555

Published: 2016

Journal Articles

Pro-Coagulant and Pro-Inflammatory Effect of Interferon Alpha in Myeloproliferative Neoplasms

Nadine Ajzenberg, MD PhD, Dorothee Faille, PharmD, PhD, Lamia Lamrani, PhD, Stéphane Loyau, Marie-Geneviève Huisse, MD PhD, Nicolas Dumontier, PharmD, Martine Jandrot-Perrus, MD PhD, Sawsaneh Alkhaier, Bruno Cassinat, PharmD, PhD, Christine Chomienne, MD PhD, Christine Dosquet, MD PhD

Blood (2016) 128 (22): 1941.

https://doi.org/10.1182/blood.V128.22.1941.1941

Published: 2016

Journal Articles

Clinical and molecular response to interferon-α therapy in essential thrombocythemia patients with CALR mutations

Emmanuelle Verger, Bruno Cassinat, Aurélie Chauveau, Christine Dosquet, Stephane Giraudier, Marie-Hélène Schlageter, Jean-Christophe Ianotto, Mohammed A. Yassin, Nader Al-Dewik, Serge Carillo, Eric Legouffe, Valerie Ugo, Christine Chomienne, Jean-Jacques Kiladjian

Blood (2015) 126 (24): 2585–2591.

https://doi.org/10.1182/blood-2015-07-659060

Published: 2015

Journal Articles

Final Results of a Phase 1 Study of 18F-FLT Positron Emission Tomography (PET)/Computed Tomography Imaging in Myelofibrosis ( FLT-MF-2009 Study)

Annalisa Andreoli, MD, Laetitia Vercellino, MD, Matthieu John Ouvrier, MD, Emmanuelle Barré, PharmD, Bruno Cassinat, PharmD, PhD, Virginie de Beco, PharmD, Pascal Merlet, MD PhD, Christine Dosquet, MD PhD, Christine Chomienne, MD PhD, Sylvie Chevret, MD PhD, Marie-Elisabeth Toubert, MD, Jean-Jacques Kiladjian, MD PhD

Blood (2014) 124 (21): 3195.

https://doi.org/10.1182/blood.V124.21.3195.3195

Published: 2014

Journal Articles

Aspirin in Philadelphia-Negative Myeloproliferative Neoplasms: What Is the Optimal Dose ?

Nadine Ajzenberg, MD PhD, Dorothee Faille, PharmD, PhD, Marie-Genevieve Huisse, MD PhD, Anh Hong Cung, Pharm D, Lamia Lamrani, Nicolas Dumontier, Pharm D, Martine Jandrot-Perrus, MD PhD, Bruno Cassinat, PharmD, PhD, Christine Chomienne, MD PhD, Christine Dosquet, MD PhD

Blood (2014) 124 (21): 3200.

https://doi.org/10.1182/blood.V124.21.3200.3200

Published: 2014

Journal Articles

Impact of the Molecular Profile of Malignant Clones on the Response to Interferon Alpha (IFNa) Therapy in JAK2V617F-Negative Essential Thrombocythemia (ET)

Emmanuelle Verger, PhD, Bruno Cassinat, PharmD, PhD, Christine Dosquet, MD PhD, Marie-Helene Schlageter, Valérie Ugo, MD PhD, Jean-Christophe Ianotto, MD, Mohamed A. Yassin, MBBS ,MSc,CABM,FACP, Nader Dewik, PhD, Serge Carillo, PhD, Christine Chomienne, MD PhD, Jean-Jacques Kiladjian, MD PhD

Blood (2014) 124 (21): 407.

https://doi.org/10.1182/blood.V124.21.407.407

Published: 2014

Journal Articles

18 F-FLT Positron Emission Tomography (PET)/CT Imaging in Myelofibrosis: A Non Invasive Method to Assess Bone Marrow Function and Extramedullary Hematopoiesis

Annalisa Andreoli, MD, Laetitia Vercellino, Mathieu-John Ouvrier, Emmanuelle Barré, Bruno Cassinat, PharmD, PhD, Virginie de Beco, Jean-Marc Zini, MD, PhD, Pascal Merlet, MD, Christine Dosquet, MD, Christine Chomienne, MD, PhD, Marie-Elisabeth Toubert, Jean-Jacques Kiladjian, MD, PhD

Blood (2012) 120 (21): 1741.

https://doi.org/10.1182/blood.V120.21.1741.1741

Published: 2012

Journal Articles

The JAK2 46/1 haplotype in splanchnic vein thrombosis

Eirini Kouroupi, Jean-Jacques Kiladjian, Christine Chomienne, Christine Dosquet, Sylvia Bellucci, Dominique Valla, Bruno Cassinat

Blood (2011) 117 (21): 5777–5778.

https://doi.org/10.1182/blood-2011-03-343657

Published: 2011

Journal Articles

EMMPRIN promotes angiogenesis through hypoxia-inducible factor-2α–mediated regulation of soluble VEGF isoforms and their receptor VEGFR-2

Faten Bougatef, Cathy Quemener, Sabrina Kellouche, Benyoussef Naïmi, Marie-Pierre Podgorniak, Guy Millot, Eric E. Gabison, Fabien Calvo, Christine Dosquet, Céleste Lebbé, Suzanne Menashi, Samia Mourah

Blood (2009) 114 (27): 5547–5556.

https://doi.org/10.1182/blood-2009-04-217380

Published: 2009

Includes: Supplemental data

Journal Articles

Long-Term Outcome in Polycythemia Vera (PV): Final Analysis of a Randomized Trial Comparing Hydroxyurea (HU) to Pipobroman (Pi).

Jean-Jacques Kiladjian, Sylvie Chevret, Christine Dosquet, Pierre Fenaux, Christine Chomienne, Jean-Didier Rain

Blood (2008) 112 (11): 1746.

https://doi.org/10.1182/blood.V112.11.1746.1746

Published: 2008

Journal Articles

Mutations in the Exon 12 of the JAK2 Gene Appeared To Be a Rare Event Essentially Clustered in V617F JAK2 Negative PV Patients.

Eirini Kouroupi, MD, Nathalie Parquet, MD, Christine Zoi, MD, Jean-Jacques Kiladjian, MD, Vassiliki Grigoraki, MD, Katerina Zoi, PhD, Linda Scott, PhD, Christine Dosquet, MD, Pierre Fenaux, MD, PhD, Dimitris Loukopoulos, MD, PhD, Christine Chomienne, MD, PhD, Bruno Cassinat, PharmD

Blood (2007) 110 (11): 2534.

https://doi.org/10.1182/blood.V110.11.2534.2534

Published: 2007

NARROW

Impact of NFE2 mutations on AML transformation and overall survival in patients with myeloproliferative neoplasms

Chronic Exposure to Cytoreductive Treatment Shapes Clonal Evolution in Myeloproliferative Neoplasms

Myeloproliferative Neoplasms (MPN) Clonal Evolution Landscape and Its Impact on Patients' Prognosis

NFE2 Mutations Impact AML Transformation and Overall Survival in Patients with Myeloproliferative Neoplasms (MPN)

SF3B1 mutations in the Driver Clone Increase the Risk of Evolution to Myelofibrosis in Patients with Myeloproliferative Neoplasms (MPN)

Long Term Outcome of Patients with MPN-Associated Myelofibrosis Treated with Peg-Interferon-α2a, a French Intergroup of Myeloproliferative Neoplasms (FIM) Study

Outcomes of Patients with Myeloproliferative Neoplasms (MPN) after Interferon-Alpha (IFN) Therapy Discontinuation

Autologous 111 Indium-Oxinate-Labelled Platelet Sequestration Study in Patients with Immune Thrombocytopenia Treated By Thrombopoietic Receptor-Agonists

Pro-Coagulant and Pro-Inflammatory Effect of Interferon Alpha in Myeloproliferative Neoplasms

Clinical and molecular response to interferon-α therapy in essential thrombocythemia patients with CALR mutations

Final Results of a Phase 1 Study of 18F-FLT Positron Emission Tomography (PET)/Computed Tomography Imaging in Myelofibrosis ( FLT-MF-2009 Study)

Aspirin in Philadelphia-Negative Myeloproliferative Neoplasms: What Is the Optimal Dose ?

Impact of the Molecular Profile of Malignant Clones on the Response to Interferon Alpha (IFNa) Therapy in JAK2V617F-Negative Essential Thrombocythemia (ET)

18 F-FLT Positron Emission Tomography (PET)/CT Imaging in Myelofibrosis: A Non Invasive Method to Assess Bone Marrow Function and Extramedullary Hematopoiesis

The JAK2 46/1 haplotype in splanchnic vein thrombosis

EMMPRIN promotes angiogenesis through hypoxia-inducible factor-2α–mediated regulation of soluble VEGF isoforms and their receptor VEGFR-2

Long-Term Outcome in Polycythemia Vera (PV): Final Analysis of a Randomized Trial Comparing Hydroxyurea (HU) to Pipobroman (Pi).

Mutations in the Exon 12 of the JAK2 Gene Appeared To Be a Rare Event Essentially Clustered in V617F JAK2 Negative PV Patients.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only